Scarica l'app Stockscreener
98.41
1.98%
1.91
Dopo l'orario di chiusura:
98.41
Precedente Chiudi:
$96.50
Aprire:
$94.85
Volume 24 ore:
2.20M
Relative Volume:
1.33
Capitalizzazione di mercato:
$7.51B
Reddito:
$8.10B
Utile/perdita netta:
$599.48M
Rapporto P/E:
13.30
EPS:
7.3969
Flusso di cassa netto:
$971.50M
1 W Prestazione:
+22.89%
1M Prestazione:
-46.11%
6M Prestazione:
-45.22%
1 anno Prestazione:
-48.56%
Intervallo 1D:
$92.59
$99.52
Intervallo di 1 settimana:
$81.31
$99.52
Portata 52W:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Nome
Icon Plc
Settore
Industria
Telefono
-
Indirizzo
-
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
98.41 | 7.37B | 8.10B | 599.48M | 971.50M | 7.3969 |
|
TMO
Thermo Fisher Scientific Inc
|
515.12 | 192.95B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
211.25 | 147.43B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
630.73 | 50.70B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
126.34 | 35.90B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
328.66 | 32.13B | 3.17B | 642.63M | 539.81M | 10.77 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2026-02-12 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-08 | Downgrade | Truist | Buy → Hold |
| 2025-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-11-13 | Iniziato | BMO Capital Markets | Market Perform |
| 2025-09-09 | Downgrade | Jefferies | Buy → Hold |
| 2025-09-03 | Aggiornamento | Rothschild & Co Redburn | Neutral → Buy |
| 2025-08-21 | Downgrade | Citigroup | Buy → Neutral |
| 2025-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-04-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-14 | Downgrade | TD Cowen | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-10-14 | Iniziato | Redburn Atlantic | Neutral |
| 2024-09-18 | Iniziato | Leerink Partners | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2023-12-15 | Iniziato | Truist | Buy |
| 2023-09-13 | Iniziato | TD Cowen | Outperform |
| 2023-01-17 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-01-13 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-11-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-09-07 | Iniziato | UBS | Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-09-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-14 | Iniziato | Citigroup | Neutral |
| 2021-04-13 | Ripresa | BofA Securities | Neutral |
| 2021-04-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-03-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-03-03 | Iniziato | Barclays | Equal Weight |
| 2021-03-01 | Aggiornamento | UBS | Neutral → Buy |
| 2021-02-26 | Aggiornamento | Truist | Hold → Buy |
| 2020-07-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Hold |
| 2020-01-27 | Downgrade | SunTrust | Buy → Hold |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-09-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-07-26 | Aggiornamento | UBS | Sell → Neutral |
| 2019-01-25 | Aggiornamento | Mizuho | Neutral → Buy |
| 2018-10-26 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-09 | Iniziato | UBS | Sell |
| 2018-04-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-15 | Reiterato | Mizuho | Neutral |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
| 2017-10-27 | Reiterato | Barclays | Equal Weight |
| 2017-09-11 | Iniziato | BofA/Merrill | Buy |
| 2017-07-31 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-27 | Reiterato | Mizuho | Neutral |
| 2017-06-29 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Icon Plc Borsa (ICLR) Ultime notizie
73,467 Shares in Icon Plc $ICLR Purchased by Muhlenkamp & Co. Inc. - MarketBeat
TD Cowen upgrades ICON stock on valuation after accounting probe By Investing.com - Investing.com Nigeria
ICON INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Icon plc: Accounting Probe Sell-Off Creates Compelling Value Despite Modest EPS Impact - TipRanks
2026-02-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON plc (ICLR) and Encourages Investors to Learn More About the Investigation | NDAQ:ICLR | Press Release - Stockhouse
ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement - GuruFocus
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer - Benzinga
TD Cowen upgrades ICON stock on valuation after accounting probe - Investing.com
Icon Plc $ICLR Shares Sold by Eagle Health Investments LP - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ICON plc (ICLR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
ICON Faces Investor Lawsuit Investigation - Intellectia AI
ICON (ICLR) stock slides as Rothschild Redburn cuts rating, extending pressure from accounting probe - Bez Kabli
Icon PLC headcount plummets 1,800 in a year amid ‘strong cost control’ - MSN
ICLR ALERT: Securities Fraud Investigation by Block & Leviton Could Allow ICON pcl Investors to Recover Losses - TradingView
Rothschild downgrades ICON stock on accounting investigation By Investing.com - Investing.com
ICON plc (ICLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ICON plc (ICLR) Stock Analysis: Unveiling an 87.74% Potential Upside in Healthcare Diagnostics - DirectorsTalk Interviews
Clinical Research Provider Icon Stock Crashes On Accounting Probe - AOL.com
ICON (ICLR) Is Down 38.2% After Internal Revenue Probe And Pulled 2025 OutlookWhat's Changed - simplywall.st
Market briefs: ECB extends interest rate pause and Birkenstock misses estimate - Business Post
ICON Public Limited Company (ICLR) Delays Earnings Amid Internal Investigation - Finviz
Icon’s Price Target Revisions Amid Strategic Expansions and New Partnerships - timothysykes.com
US law firms circle Icon PLC after revelations of accounting probe send shares plunging - The Irish Independent
ICON PLC (ICON) soars 16% as analyst issues 'hold', $93 PT despite accounting concerns - MSN
ICON PLC (ICON) Soars 16% as Analyst Issues 'Hold', $93 PT Despite Accounting Concerns - Finviz
ICON PLC (ICON) Soars 16% as Analyst Issues ‘Hold’, $93 PT Despite Accounting Concerns - Insider Monkey
ICON plc (ICLR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ICON (ICLR) stock rebounds after accounting probe shock — what investors watch next - Bez Kabli
ICON plc Expands Oncology Research, Sets New Price Target - StocksToTrade
Icon Strategy Expands with New Partnership to Bolster Oncology Research - timothysykes.com
ICON Expands Oncology Research Capabilities Amidst Positive Stock Reevaluation - StocksToTrade
ICON plc Expands Clinical Trial Capabilities through Strategic Partnership - timothysykes.com
Icon Partners with Brian Moran for Key Oncology Expansion - StocksToTrade
ICON plc Expands Oncology Network, Stock Assessment and Market Analysis - timothysykes.com
ICON plc Expands Oncology Research, Price Target Upgraded - StocksToTrade
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Investigation Into Revenue Recognition IssuesHagens Berman - The Malaysian Reserve
ICON (ICLR) Is Down 44.9% After Probing Revenue Recognition And Control WeaknessesWhat's Changed - Yahoo Finance
Truist Financial Maintains Icon PLC(ICLR.US) With Hold Rating - 富途牛牛
ICON plc (ICLR) Shares Crater Amid Delayed Financial Report, Inv - GuruFocus
ICON (ICLR) stock steadies premarket after 40% crash on accounting probe — what’s next - Bez Kabli
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ICON plc (ICLR) And Encourages Investors to Reach Out - ACCESS Newswire
Icon PLC stock hits 52-week low at $79.49 By Investing.com - Investing.com Australia
Here's How Much $100 Invested In Icon 20 Years Ago Would Be Worth Today - Sahm
ICON stock plummets after accounting investigation delays earnings By Investing.com - Investing.com
ICON stock rating suspended by Evercore amid accounting investigation By Investing.com - Investing.com Canada
ICON stock rating downgraded by BofA Securities amid accounting concerns - Investing.com UK
Ademi LLP Investigates Claims of Securities Fraud against ICON plc - The Malaysian Reserve
ICON Public Limited Company Under Investigation for Securities Law Violations - Intellectia AI
ICON plc Shares Plunge 49% Amid Revenue Recognition Investigation - Intellectia AI
ICON plc (ICLR) Shares Crater Amid Delayed Financial - GlobeNewswire
Medtech Plummets 40% On Profit-Threatening Investigation - Investor's Business Daily
Icon Plc Azioni (ICLR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):